Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 318

1.

Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.

Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV.

Lung Cancer. 2015 Apr 22. pii: S0169-5002(15)00203-2. doi: 10.1016/j.lungcan.2015.04.004. [Epub ahead of print]

PMID:
25982012
2.

Self-hypnosis for intrapartum pain management in pregnant nulliparous women: a randomised controlled trial of clinical effectiveness.

Downe S, Finlayson K, Melvin C, Spiby H, Ali S, Diggle P, Gyte G, Hinder S, Miller V, Slade P, Trepel D, Weeks A, Whorwell P, Williamson M.

BJOG. 2015 May 11. doi: 10.1111/1471-0528.13433. [Epub ahead of print]

PMID:
25958769
3.

Letter: efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome - authors' reply.

Miller V, Carruthers H, Morris J, Hasan SS, Archbold S, Whorwell PJ.

Aliment Pharmacol Ther. 2015 Jun;41(11):1223-4. doi: 10.1111/apt.13205. No abstract available.

PMID:
25939472
4.

Promoting sex and gender to optimize clinical research and healthcare delivery.

Veldhuis K, Miller V, Kublickiene K.

Maturitas. 2015 Apr 13. pii: S0378-5122(15)00638-6. doi: 10.1016/j.maturitas.2015.03.027. [Epub ahead of print] No abstract available.

PMID:
25934602
5.

Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis.

Voloshin T, Alishekevitz D, Kaneti L, Miller V, Isakov E, Kaplanov I, Voronov E, Fremder E, Benhar M, Machluf M, Apte RN, Shaked Y.

Mol Cancer Ther. 2015 Apr 17. [Epub ahead of print]

PMID:
25887886
6.

Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients.

Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ.

Aliment Pharmacol Ther. 2015 May;41(9):844-55. doi: 10.1111/apt.13145. Epub 2015 Mar 4.

PMID:
25736234
7.

Improving evidence developed from population-level experience with targeted agents.

McClellan MB, Daniel GW, Dickson D, Perlmutter J, Berger DP, Miller V, Nussbaum S, Malin J, Romine MH, Schilsky RL.

Clin Pharmacol Ther. 2015 May;97(5):478-87. doi: 10.1002/cpt.90. Epub 2015 Apr 3.

PMID:
25676878
8.

How can we exploit the brain's ability to repair itself?

Miller V, Gomez-Nicola D.

Expert Rev Neurother. 2014 Dec;14(12):1345-8. doi: 10.1586/14737175.2014.985659.

PMID:
25427149
9.

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE.

J Thorac Oncol. 2014 Sep;9(9):1411-7. doi: 10.1097/JTO.0000000000000274.

PMID:
25122437
10.

Irritable bowel syndrome: a comparison of subtypes.

Rey de Castro NG, Miller V, Carruthers HR, Whorwell PJ.

J Gastroenterol Hepatol. 2015 Feb;30(2):279-85. doi: 10.1111/jgh.12704.

PMID:
25091059
11.

Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition.

Miller V, Grant RM.

Clin Pharmacol Ther. 2014 Aug;96(2):153-5. doi: 10.1038/clpt.2014.114. Review.

PMID:
25056397
12.

HIV and hepatitis C virus infection in the United States: whom and how to test.

Panneer N, Lontok E, Branson BM, Teo CG, Dan C, Parker M, Stekler JD, DeMaria A Jr, Miller V.

Clin Infect Dis. 2014 Sep 15;59(6):875-82. doi: 10.1093/cid/ciu396. Epub 2014 May 27. Review.

PMID:
24867787
13.

Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group.

Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V.

Clin Pharmacol Ther. 2014 Aug;96(2):162-5. doi: 10.1038/clpt.2014.113. Epub 2014 May 22. Review.

PMID:
24853733
14.

A multitiered strategy of simulation training, kit consolidation, and electronic documentation is associated with a reduction in central line-associated bloodstream infections.

Allen GB, Miller V, Nicholas C, Hess S, Cordes MK, Fortune JB, Blondin J, Ashikaga T, Ricci M.

Am J Infect Control. 2014 Jun;42(6):643-8. doi: 10.1016/j.ajic.2014.02.014.

PMID:
24837115
15.

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K.

Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9.

16.

Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles.

Munster M, Fremder E, Miller V, Ben-Tsedek N, Davidi S, Scherer SJ, Shaked Y.

PLoS One. 2014 Apr 21;9(4):e95983. doi: 10.1371/journal.pone.0095983. eCollection 2014.

17.

Regoaling: a conceptual model of how parents of children with serious illness change medical care goals.

Hill DL, Miller V, Walter JK, Carroll KW, Morrison WE, Munson DA, Kang TI, Hinds PS, Feudtner C.

BMC Palliat Care. 2014 Mar 13;13(1):9. doi: 10.1186/1472-684X-13-9.

18.

Beneficial impact of antiretroviral therapy on non-AIDS mortality.

Miller V, Hodder S.

AIDS. 2014 Jan 14;28(2):273-4. doi: 10.1097/QAD.0000000000000079. No abstract available.

PMID:
24413312
19.

Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.

Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B, Shaked Y.

Int J Cancer. 2014 Jul 15;135(2):270-81. doi: 10.1002/ijc.28678. Epub 2014 Jan 13.

PMID:
24347266
20.

Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.

Alishekevitz D, Bril R, Loven D, Miller V, Voloshin T, Gingis-Velistki S, Fremder E, Scherer SJ, Shaked Y.

Mol Cancer Ther. 2014 Jan;13(1):202-13. doi: 10.1158/1535-7163.MCT-13-0356. Epub 2013 Oct 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk